Clinical Trial of TJ271 Injection Combined With Pabolizumab in the Treatment of Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
A Multi-center, Open-label Phase II Clinical Trial of TJ271 Injection in Combination with
Pembrolizumab in Chinese Patients with Advanced Solid Tumors to evaluate the anti-tumor
efficacy, safety, pharmacokinetics and immunogenicity of TJ271 in combination with
pembrolizumab in patients with advanced solid tumors.